[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100640414":3},{"organization":4,"armGroups":7,"interventions":7,"overallOfficials":8,"centralContacts":13,"locations":7,"responsibleParty":22,"collaborators":7,"id":26,"slug":27,"hasResults":28,"nctId":29,"briefTitle":30,"officialTitle":31,"acronym":32,"eligibilityCriteria":33,"healthyVolunteers":28,"sex":34,"minAge":35,"maxAge":36,"enrollmentInfo":37,"targetDuration":40,"studyType":41,"phases":7,"briefSummary":42,"conditions":43,"keywords":48,"overallStatus":55,"whyStopped":7,"lastUpdateSubmitDate":56,"lastUpdatePostDateStruct":57,"startDateStruct":60,"completionDateStruct":62,"leadSponsor":64,"locationsCount":7},{"fullName":5,"class":6},"Northern Jiangsu People's Hospital","OTHER",null,[9],{"name":10,"affiliation":11,"role":12},"Guo-Qing Jiang, MD","Clinical Medical College of Yangzhou University","STUDY_CHAIR",[14,18],{"name":10,"role":15,"phone":16,"phoneExt":7,"email":17},"CONTACT","+8651487373272","jgqing2003@hotmail.com",{"name":19,"role":15,"phone":20,"phoneExt":7,"email":21},"Dou-Sheng Bai, MD","+8651487373372","bdsno1@hotmail.com",{"type":23,"investigatorFullName":24,"investigatorTitle":25,"investigatorAffiliation":5,"oldNameTitle":7,"oldOrganization":7},"PRINCIPAL_INVESTIGATOR","Guo-Qing Jiang","Clinical Professor","100640414","effect-of-lsd-on-renal-function-in-cirrhosis-patients-with-portal-hypertension-bleeding-2-year-follow-up-100640414",false,"NCT07585786","Effect of LSD on Renal Function in Cirrhosis Patients With Portal Hypertension Bleeding (2-Year Follow-Up)","A Prospective, Single-Center, Observational Cohort Study to Evaluate the Long-Term (2-Year) Effects of Laparoscopic Splenectomy and Azygoportal Disconnection on Renal Function in Patients With Liver Cirrhosis, Portal Hypertension Bleeding","LSD-RFPH","Inclusion Criteria:\n\n1. Confirmed diagnosis of liver cirrhosis (clinical, laboratory, imaging)\n2. Splenomegaly and hypersplenism\n3. History of portal hypertension bleeding (esophageal and gastric variceal bleeding )\n4. Age 18-80 years, male or female\n5. Child-Pugh Class A or B liver function\n6. No history of primary renal disease or acute kidney injury (AKI)\n7. Signed written informed consent\n8. Ability to complete 24-month follow-up\n\nExclusion Criteria:\n\n1. Child-Pugh Class C liver cirrhosis\n2. Primary renal diseases (glomerulonephritis, polycystic kidney disease, chronic pyelonephritis, etc.)\n3. Previous abdominal surgery precluding safe laparoscopic splenectomy and azygoportal disconnection\n4. Severe cardiac, pulmonary, cerebrovascular dysfunction; malignant tumors; primary hematological disorders\n5. Hepatic encephalopathy or refractory ascites within 1 month before surgery\n6. Pregnancy or lactation\n7. Poor compliance, inability to complete follow-up","ALL","18 Years","80 Years",{"count":38,"type":39},30,"ESTIMATED","2 Years","OBSERVATIONAL","Patients with liver cirrhosis often have impaired or at-risk kidney function due to the close link between liver and kidney (hepatorenal syndrome). Laparoscopic Splenectomy and Azygoportal Disconnection (LSD) is commonly used to treat Cirrhosis with Portal Hypertension Bleeding in these patients, but its impact on kidney function over 2 years is unclear. This study will follow patients undergoing laparoscopic splenectomy to measure changes in kidney function before and after surgery, identify risk factors for kidney damage and whether LSD can improve kidney function in the long term, and help improve care to protect kidney function in cirrhotic patients .",[44,45,46,47],"Cirrhosis, Liver","Splenectomy; Status","Renal Function Abnormal","Portal Hypertension",[49,50,51,52,53,54],"Cirrhosis","Splenectomy","Laparoscopy","azygoportal disconnection","Renal function","Portal hypertension bleeding","NOT_YET_RECRUITING","2026-05-14",{"date":58,"type":59},"2026-05-18","ACTUAL",{"date":61,"type":39},"2026-05-01",{"date":63,"type":39},"2029-02-28",{"name":5,"class":6}]